StreetInsider.com News Articles

Form 8-K PTC THERAPEUTICS, INC. For: Jun 18

Thu, 18 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260618/26666214.html

Form 8-K PTC THERAPEUTICS, INC. For: Jun 18

Thu, 18 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260618/26666214.html

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:30:00 -0400

WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:30:00 -0400

The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:30:00 -0400

The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 17 Jun 2026 16:30:00 -0400

The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Wed, 17 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260617/26659948.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Wed, 17 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260617/26659948.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Utter Christine Marie

Wed, 17 Jun 2026 09:39:00 -0400

si-local-file:///var/storage/secattach/20260617/26657954.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Utter Christine Marie

Wed, 17 Jun 2026 09:39:00 -0400

si-local-file:///var/storage/secattach/20260617/26657954.html

Form 8-K PTC THERAPEUTICS, INC. For: Jun 15

Tue, 16 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26650268.html

Form 8-K PTC THERAPEUTICS, INC. For: Jun 15

Tue, 16 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26650268.html

PTC Therapeutics prices $500M convertible notes at 0% to refinance 2026 debt

Tue, 16 Jun 2026 03:54:48 -0400

PTC Therapeutics, Inc. (NASDAQ: PTCT) has priced $500.0 million in aggregate principal amount of 0% Convertible Senior Notes due 2031 in a private placement to qualified institutional buyers under Rule 144A.

The notes carry no regular interest and mature on June 15, 2031. The initial conversion price is approximately $107.48 per share, representing a 40% premium over PTC's closing stock price of $76.77 on the Nasdaq Global Select Market on June 15, 2026. The conversion rate is set at 9.3042 shares per $1,000 principal amount.

PTC also granted initial purchasers an option to buy up to an additional $50.0 million in notes

PTC Therapeutics prices $500M convertible notes at 0% to refinance 2026 debt

Tue, 16 Jun 2026 03:54:48 -0400

PTC also granted initial purchasers an option to buy up to an additional $50.0 million in notes

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 23:14:00 -0400

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –

WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 23:14:00 -0400

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 23:14:00 -0400

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 23:14:00 -0400

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –

PTC Therapeutics proposes $500 million convertible notes offering

Mon, 15 Jun 2026 07:00:44 -0400

PTC Therapeutics Inc. (NASDAQ: PTCT) announced plans to offer $500 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers. The company intends to grant initial purchasers an option to purchase up to $50 million in additional notes within 13 days of issuance.

The notes will mature on June 15, 2031, unless converted, repurchased or redeemed earlier. Upon conversion, PTC will pay cash, shares of common stock, or a combination of both at the company's discretion. Interest will accrue and be paid semiannually.

PTC expects to use net proceeds to repurchase a portion of its 1.5% convertible

PTC Therapeutics proposes $500 million convertible notes offering

Mon, 15 Jun 2026 07:00:44 -0400

PTC expects to use net proceeds to repurchase a portion of its 1.5% convertible

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 07:00:00 -0400

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –

– Offering to include buyback of common stock –

WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 07:00:00 -0400

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –

– Offering to include buyback of common stock –

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 07:00:00 -0400

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –

– Offering to include buyback of common stock –

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

Mon, 15 Jun 2026 07:00:00 -0400

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity –

– Offering to include buyback of common stock –

Form 4 PTC THERAPEUTICS, INC. For: Jun 10 Filed by: Pauwels Eric

Fri, 12 Jun 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260612/26642235.html